Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease

Journal of Cystic Fibrosis

Volumn 9, Issue 3, 2010, Pages 228-233

  Risé, Patrizia ^a   Volpi, Sonia ^b   Colombo, Claudio ^a   Padoan, Rita Francesca ^c   D'Orazio, Ciro ^b   Ghezzi, Silvia ^a   Melotti, Paola ^b   Bennato, Veronica ^c   Agostoni, Carlo ^a   Assael, Baroukh Maurice ^b   Galli, Claudio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Department of Pediatrics   (Italy)

Author keywords

Cystic fibrosis; Fatty acid desaturation; Pulmonary disease; Whole blood fatty acids

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; LINOLEIC ACID; MONOUNSATURATED FATTY ACID; OLEIC ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; ACYL COENZYME A DESATURASE; BIOLOGICAL MARKER; DELTA-5 FATTY ACID DESATURASE; UNSATURATED FATTY ACID;

ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID DESATURATION; FATTY ACID METABOLISM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LIPID COMPOSITION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; ADOLESCENT; BLOOD; BLOOD SAMPLING; CASE CONTROL STUDY; DISEASE COURSE; GAS CHROMATOGRAPHY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, GAS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FATTY ACID DESATURASES; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; YOUNG ADULT;

EID: 77953356014     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.03.002     Document Type: Article

References (29)

1. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
2. Quinton P.M. Missing Cl conductance in cystic fibrosis. Am J Physiol 1986, 251:C649-C652.
3. Kerem E., Corey M., Kerem B.S., Rommens J., Markiewicz D., Levison H., et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (DF508). N Eng J Med 1990, 323:1517-1522.
4. Minasian C., Mc Cullagh A., Bush A. Cystic fibrosis in neonates and infants. Early Hum Dev 2005, 81:997-1004.
5. Farrell P.M., Mischler E.H., Engle M.J., Brown D.J., Lau S. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985, 19:104-109.
6. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice. Proc Natl Acad Sci U S A 1999, 96:13995-14000.
7. Levistre R., Lemnaouar M., Rybkine T., Béréziat G., Masliah J. Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. Biochim Biophys Acta 1993, 1181:233-239.
8. Miele L., Cordella-Miele E., Xing M., Frizzell R., Mukherjee A.B. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol 1997, 16:749-759.
9. McKarney C., Everard M.L., D'Diaje T. Omega 3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev 2007, 4. Art. No.: CD002201. 10.1002/14651858.CD002201.pub2.
10. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr 2003, 27:52-57.
11. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004, 350:560-569.
12. Marangoni F., Colombo C., Galli C. A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies. Anal Biochem 2004, 326:267-272.
13. Marangoni F., Colombo C., Martiello A., Negri E., Galli C. The fatty acid profiles in a drop of blood from a fingertip correlate with physiological, dietary and lifestyle parameters in volunteers. Prost Leukot Ess Fatty Acids 2007, 76:87-92.
14. Risé P., Eligini S., Ghezzi S., Colli S., Galli C. Fatty acid composition of plasma, blood cells and whole blood: relevance for the assessment of the fatty acid status in humans. Prost Leukot Ess Fatty Acids 2007, 76:363-369.
15. Standardization of Spirometry American Thoracic Society. Am J Respir Crit Care Med 1995, 152:1107-1136. Update.
16. Agostoni C., Giovannini M., Sala D., Usuelli M., Livio L., Francescato G., et al. Double-blind, placebo-controlled trial comparing effects of supplementation of two micronutrient sprinkles on fatty acid status in Cambodian infants. J Pediatr Gastroenterol Nutr 2007, 44:136-142.
17. Colombo C., Bennato V., Costantini D., Valmarana L., Daccò V., Zazzeron L., et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes?. J Pediatr Gastroenterol Nutr 2006, 43:660-665.
18. Keen C., Olin A.C., Edentoft A., Gronowitz E., Strandvik B. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, pseudomonas infection, and polyunsaturated fatty acids. Chest 2007, 131:1857-1864.
19. Coste T.C., Deumer G., Reychler G., Lebecque P., Wallemacq P., Leal T. Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. Clin Chem 2008, 54:388-395.
20. Strandvik B., Gronowitz E., Enlund F., Martinsson T., Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001, 138:650-655.
21. Olveira G., Dorado A., Olveira C., Padilla A., Rojo-Martinez G., Garcia-Escobar E., et al. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br J Nutr 2006, 96:343-349.
22. Solakivi T., Jaakkola O., Kalela A., Pispa M., Salomaki A., Lehtimaki T., et al. Lipoprotein docosapentaenoic acid is associated with serum matrix metalloproteinase-9 concentration. Lipids Health Dis 2005, 4:8-12.
23. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39:224-232.
24. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
25. Mekus F., Ballmann M., Bronsveld I., Bijman J., Veeze H., Tummler B. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 2000, 3:277-293.
26. Gibson R.A., Teubner J.K., Haines K., Cooper D.M., Davidson G.P. Relationships between pulmonary functions and plasma fatty acid levels in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1986, 5:408-415.
27. Maqbool A., Shall J., Zemel B., Strandvik B., Virginia S.A. Essential fatty acid status and growth and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 2004, S27:337.
28. Van Biervliet S., Vanbillemont G., Van Biervliet J., Declercq D., Robberecht E., Christophe A. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients. Ann Nutr Metab 2007, 51:541-549.
29. Batal I., Ericsoussi M.H.D.B., Clouette-Brown J.E., O'Sullivan B.P., Freedman S.D., Savaille J.E., et al. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin Chem 2007, 53:78-84.